Posted inBiotechnology
BMS pays Leqembi originator $100M for next-gen preclinical Alzheimer’s prospects
Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 million…
Posted inBiotechnology
Roche reports failure of Prothena-partnered Parkinson’s prospect in phase 2b but highlights positives
Back-to-back clinical failures have dealt further blows to efforts to treat Parkinson’s disease by targeting alpha-synuclein. Days after UCB reported the…
Posted inBiotechnology
Astellas pays Sangamo $20M upfront to improve neurological gene therapy capabilities
Astellas is continuing to strengthen its neurological disease gene therapy capabilities, handing Sangamo Therapeutics $20 million upfront to help bypass…
Posted inBiotechnology
XGEN Venture closes $190M fund with plans to invest in early-stage biotech, medtech firms
Italian VC XGEN Venture has closed a 180 million euro ($190 million) fund for biotech and medtech companies. The life…
Posted inBiotechnology
Alphabet spinoff SandboxAQ raises $300M fund for ‘next wave of AI’
Alphabet spinoff SandboxAQ has raised more than $300 million to go toward developing AI applications across multiple areas including drug…
Posted inBiotechnology
Lawsuit accuses Applied Therapeutics of misleading investors before FDA rejection
After its rare disease drug was rejected by the FDA in late November, Applied Therapeutics vowed to fight on with…
Posted inBiotechnology
Editor’s Corner: Fierce Biotech’s 10 most-read stories of 2024
For the end of this year, Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting.…
Posted inBiotechnology
Ring Therapeutics lays off just under half of staff in 2nd wave of cuts this year, CEO set to step down
Ring Therapeutics, a Flagship Pioneering-backed biotech developing new viral vectors for gene therapy delivery, has cut its staff by just…
Posted inBiotechnology
Novartis, BioAge take on age-related diseases in $550M pact
Freshly public BioAge Labs has secured a multi-year partnership with Novartis that focuses on age-related diseases and includes the possibility…
Posted inBiotechnology
Fibrosis-focused Tvardi to go public via merger with cash-strapped Cara
Pruritus drug developer Cara Therapeutics kicked off the year halving its headcount, and the biotech has now found a new…